Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1823565
Max Phase: Preclinical
Molecular Formula: C25H21NaO6S2
Molecular Weight: 482.58
Molecule Type: Small molecule
Associated Items:
ID: ALA1823565
Max Phase: Preclinical
Molecular Formula: C25H21NaO6S2
Molecular Weight: 482.58
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C([O-])[C@@]1(O)C[C@@H](O)[C@H](O)C(OCc2ccc3sccc3c2)=C1Cc1ccc2sccc2c1.[Na+]
Standard InChI: InChI=1S/C25H22O6S2.Na/c26-19-12-25(30,24(28)29)18(11-14-1-3-20-16(9-14)5-7-32-20)23(22(19)27)31-13-15-2-4-21-17(10-15)6-8-33-21;/h1-10,19,22,26-27,30H,11-13H2,(H,28,29);/q;+1/p-1/t19-,22+,25-;/m1./s1
Standard InChI Key: ZUWXZTJDMFMDRG-DCTXAINWSA-M
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 482.58 | Molecular Weight (Monoisotopic): 482.0858 | AlogP: 4.07 | #Rotatable Bonds: 6 |
Polar Surface Area: 107.22 | Molecular Species: ACID | HBA: 7 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 4.28 | CX Basic pKa: | CX LogP: 3.14 | CX LogD: 0.16 |
Aromatic Rings: 4 | Heavy Atoms: 33 | QED Weighted: 0.33 | Np Likeness Score: 0.34 |
1. Tizón L, Otero JM, Prazeres VF, Llamas-Saiz AL, Fox GC, van Raaij MJ, Lamb H, Hawkins AR, Ainsa JA, Castedo L, González-Bello C.. (2011) A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors., 54 (17): [PMID:21780742] [10.1021/jm2006063] |
Source(1):